EU RISK ASSESSMENT ON CUMYL-4CN-BINACA AS NEW PSYCHOACTIVE DRUG

On 14th May, the European Monitoring Centre for Drugs and Drug Addiction published a report that presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA), carried out by the extended Scientific Committee of the EMCDDA in November 2017.  On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14th May, the Council decided that CUMYL-4CN-BINACA should be subject to control measures across the Member States as a New Psychoactive Substance (NPS).  It is a synthetic cannabinoid receptor agonist (synthetic cannabinoid) originally patented under the code name SGT-78.

http://www.emcdda.europa.eu/publications/risk-assessments/cumyl-4cn-binaca_en

Author: raytodd2017

Chartered Legal Executive and former senior manager with Isle of Man Customs and Excise, where I was (amongst other things) Sanctions Officer (for UN/EU sanctions), Export Licensing Officer and Manager of the Legal-Library & Collectorate Support Section

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s